Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Business Wire

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Golub Capital Strengthens Commitment to Middle East Region
From Golub Capital
Via Business Wire
Media Alert: Netcracker President Sylvain Seignour to Speak During Opening Presentations at Telecom Review Leaders’ Summit
From Netcracker Technology
Via Business Wire
Avinor Selects Thales to Deploy Norway’s Next-Generation Nationwide Unmanned Traffic Management System
From Thales
Via Business Wire
U.S. DoD Awards USEUCOM BPA to SES Space & Defense
From SES
Via Business Wire
HAFNIA LIMITED: Transactions made under share buyback program
From Hafnia Limited
Via Business Wire
Tickers HAFN
Ferguson Files Form 8-K
From Ferguson Enterprises Inc.
Via Business Wire
Tickers FERG
Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
From Daiichi Sankyo
Via Business Wire
PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting
From PureTech Health plc
Via Business Wire
Tickers PRTC
Poxel Reports Financial Results for First Half 2024 and Provides an Update on its Financial Position and Outlook
From POXEL SA
Via Business Wire
Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Leukogene Therapeutics Welcomes Industry Veteran and Leader Dr. Sandeep Gupta as Its Chief Executive Officer
From Leukogene Therapeutics Inc.
Via Business Wire
Walmart Delivers Last-Minute Savings and Convenience with Holiday Grand Finale
From Walmart Inc.
Via Business Wire
Tickers WMT
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition
From Arcellx, Inc.
Via Business Wire
Tickers ACLX
Be Biopharma Unveils BeCoMe-9 Trial and Presents on Versatile B Cell Medicines Platform at ASH 2024
From Be Biopharma, Inc.
Via Business Wire
Apple announces Apple Retail expansion in the Kingdom of Saudi Arabia
From Apple
Via Business Wire
Tickers AAPL
New Results Show Donor Search Prognosis Score Equalizes Transplant Outcomes at American Society of Hematology Annual Meeting 2024
From NMDP
Via Business Wire
Orca Bio Presents Three-Year Survival Data with Orca-T® in Patients with Hematological Malignancies at the 66th ASH Annual Meeting
From Orca Bio
Via Business Wire
MTCH INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Match Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Tickers MTCH
SYM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Symbotic Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Tickers SYM
CELH INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Celsius Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Tickers CELH
ZETA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zeta Global Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Tickers ZETA
Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Tickers VRTX
Five-Year Results Confirm Genentech’s Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma
From Genentech
Via Business Wire
Tickers RHHBY
Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
From bluebird bio, Inc.
Via Business Wire
Tickers BLUE
ReAlta Life Sciences Announces Positive Preclinical Data for RLS-0071 (pegtarazimod) in Acute Graft-Versus-Host Disease (aGVHD) at American Society of Hematology Annual Meeting
From ReAlta Life Sciences, Inc.
Via Business Wire
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
From Genmab A/S
Via Business Wire
Tickers GMAB
Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
From Genmab A/S
Via Business Wire
Tickers GMAB
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.